Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.69 USD
+0.05 (3.05%)
Updated May 3, 2024 03:59 PM ET
After-Market: $1.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Brokerage Reports
Milestone Pharmaceuticals Inc. [MIST]
Reports for Purchase
Showing records 1 - 20 ( 25 total )
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Etripamil Program NDA in PSVT Expected in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Positive Type A Meeting Outcome on RTF Letter; Expect Refiling of Etripamil NDA in 2Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Compelling Valuation Ahead of FDA Interactions Regarding NDA for Lead Program Etripamil; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
FDA Seeks Clarity on Timing of Adverse Events in Etripamil Program; Path Forward to Emerge in 1H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Etripamil Blockbuster Potential Across Multiple Indications Takes Shape; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Etripamil for PSVT NDA Submission Expected in October; Phase 2 AFib Data Expected 4Q23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Outlines Potential of Etripamil in Atrial Fibrillation With RVR; Phase 2 Top-Line Data Expected 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; KOL Event on May 22 to Detail Opportunity in Atrial Fibrillation; Etripamil NDA Filing on Track for 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Etripamil in PSVT NDA Submission on Track for 2H23; $125M Strategic Financing to Support Potential Launch
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
FDA Feedback Supports and Aligns With Etripamil NDA Submission in 3Q23; Potential Approval on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Commercial Deep Dive Depicts Path to Successful Etripamil Launch, With Blockbuster Revenue Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Sell-Off Post-Phase 3 RAPID Results is Overdone; Positive Data Presented at AHA 2022; Upping PT to $25; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
RAPID Phase 3 Program Meets Primary Endpoint; Etripamil on Track for Potential Approval for PSVT in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
RAPIDly Approaching Phase 3 Data on Potential Blockbuster Program Etripamil in PSVT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Potential Blockbuster Etripamil Program Expected to Generate Phase 3 Data in Mid-2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Positive Data Emerges From Phase 3 Open-Label Extension Trial on Lead Compound Etripamil; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
KOL Event Highlights Etripamil Potential in PSVT; Phase 3 Topline Data on Track for Mid-2H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
4Q21 Results; Phase 3 Data On Lead Program Etripamil On Track For Mid-2H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Milestone Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
New Compelling Data Emerges From Lead Program Etripamil at AHA 2021
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P